Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]

Trial Profile

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms ELLACTO
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Feb 2018 Planned initiation date changed from 5 Feb 2018 to 26 Feb 2018.
    • 07 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top